Insider · CIK 0001959178
Byong Kim
Files at LIPO (LIPELLA PHARMACEUTICALS INC). First filing -, latest -.
In brief
Byong Kim files SEC Form 4 as director at LIPO (LIPELLA PHARMACEUTICALS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Byong Kim has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 15, 2024 | LIPO LIPELLA PHARMACEUTICALS INC | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Mar 19, 2024 |
Questions about Byong Kim
Answered from the filings on this page, as of the latest one.
Is Byong Kim buying or selling?
Byong Kim has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Byong Kim's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Byong Kim has 0.
Where does Byong Kim file Form 4?
Byong Kim has filed Form 4 at LIPO (LIPELLA PHARMACEUTICALS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.